Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017
November 09 2017 - 4:30PM
Business Wire
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage
clinical oncology company advancing novel product candidates based
on its Targeted Protein Therapeutics (TPTs) platform, today
announced it will host a live conference call and webcast at 4:30
p.m. ET on Tuesday, November 14, 2017 to report its third quarter
2017 financial results and provide a corporate update.
To access the conference call, please dial (844) 831-3025
(domestic) or (315) 625-6887 (international) at least five minutes
prior to the start time and refer to conference ID 3890769. An
audio webcast of the call will also be available on the Investors
& Media section of the Company’s website, www.elevenbio.com. An
archived webcast will be available on the Company’s website
approximately two hours after the event and will be available for
30 days.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late-stage, clinical oncology
company advancing novel product candidates based upon the Company’s
targeted protein therapeutics (TPTs) platform. TPTs incorporate a
tumor-targeting antibody fragment and a protein cytotoxic payload
into a single protein molecule in order to achieve focused tumor
cell killing. Eleven’s lead TPT, Vicinium, is currently in a Phase
3 trial in non-muscle Invasive bladder cancer, with topline
three-month data expected in mid-2018. The Company believes its TPT
approach offers significant advantages in treating cancer over
existing antibody drug conjugate technologies. The Company believes
its TPTs provide effective tumor targeting with broader cancer
cell-killing properties than are achievable with small molecule
payloads that require tumor cell proliferation and face multi-drug
resistant mechanisms. Additionally, the Company believes that its
TPT’s cancer cell-killing properties promote an anti-tumor immune
response that will potentially combine well with immune oncology
drugs such as checkpoint inhibitors. For more information, please
refer to the Company’s website at www.elevenbio.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171109006552/en/
Stern Investor Relations, Inc.Michael Schaffzin,
212-362-1200michael@sternir.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2023 to Apr 2024